北京清辉联诺生物科技

Qinghui Liannuo is a clinical-stage biotechnology company focused on developing innovative immunotherapies that leverage the unique biology of γδ T cells. Founded by a research team from Tsinghua University, the company specializes in the molecular mechanisms of γδ T cell activation, particularly the role of butyrophilin (BTN) family proteins. Their lead candidate, QH-101, is a monoclonal antibody targeting BTN3A1 designed to selectively activate γδ T cells to eliminate cancer cells. The company's pipeline includes both antibody-based and small molecule-based approaches to treat solid tumors and infectious diseases. Qinghui Liannuo aims to establish a global leadership position in the field of unconventional T cell-based drug discovery.